| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
70,010,000 |
| Market
Cap: |
616.79(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.18 - $12.9 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
2,475 |
| Total Sell Value |
$0 |
$0 |
$0 |
$20,045 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hausman Diane |
Chief Medical Officer |
• – – |
2020-12-04 |
4 |
OE |
$9.82 |
$65,662 |
D/D |
6,032 |
9,750 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-12-02 |
4 |
AS |
$55.01 |
$38,563 |
D/D |
(701) |
3,718 |
|
-45% |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-12-02 |
4 |
OE |
$9.82 |
$8,043 |
D/D |
701 |
4,419 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-12-01 |
4 |
AS |
$55.19 |
$1,008,240 |
D/D |
(18,267) |
3,718 |
|
-49% |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-12-01 |
4 |
OE |
$9.82 |
$207,955 |
D/D |
18,267 |
21,985 |
|
- |
|
| Odriscoll Kathryn |
Chief People Officer |
• – – |
2020-11-18 |
4 |
OE |
$34.24 |
$99,981 |
D/D |
2,920 |
2,920 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2020-11-02 |
4 |
S |
$39.04 |
$136,624 |
I/I |
(3,500) |
56,361 |
|
14% |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-09-14 |
4 |
AS |
$45.00 |
$1,800,000 |
D/D |
(40,000) |
3,718 |
|
11% |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-09-14 |
4 |
OE |
$9.82 |
$545,500 |
D/D |
40,000 |
43,718 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2020-07-02 |
4 |
A |
$30.66 |
$8,493 |
D/D |
277 |
9,112 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2020-07-02 |
4 |
A |
$30.66 |
$14,962 |
D/D |
488 |
29,479 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-07-02 |
4 |
A |
$30.66 |
$11,252 |
D/D |
367 |
3,718 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2020-04-13 |
4 |
OE |
$3.85 |
$3,854 |
D/D |
1,000 |
257,009 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2020-04-03 |
4 |
B |
$33.39 |
$19,199 |
I/I |
575 |
59,861 |
2.58 |
-13% |
|
| Cox Troy |
Director |
– • – |
2020-01-27 |
4 |
B |
$46.50 |
$348,750 |
D/D |
7,500 |
7,500 |
2.39 |
-19% |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2020-01-08 |
4 |
A |
$19.54 |
$7,699 |
D/D |
394 |
8,835 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2020-01-08 |
4 |
A |
$19.54 |
$7,249 |
D/D |
371 |
28,991 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-01-08 |
4 |
A |
$19.54 |
$6,487 |
D/D |
332 |
3,351 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2019-12-12 |
4 |
OE |
$15.00 |
$412,500 |
D/D |
27,500 |
28,620 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2019-07-08 |
4 |
A |
$12.49 |
$13,989 |
D/D |
1,120 |
1,120 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2019-07-08 |
4 |
A |
$12.49 |
$6,495 |
D/D |
520 |
3,019 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2019-07-08 |
4 |
A |
$12.49 |
$5,795 |
D/D |
464 |
8,441 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2019-05-06 |
4 |
S |
$19.22 |
$159,733 |
D/D |
(8,308) |
7,977 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2019-05-06 |
4 |
OE |
$2.66 |
$47,414 |
D/D |
15,084 |
9,581 |
|
- |
|
| Poon David Kai Yuen |
See Remarks |
• – – |
2019-05-06 |
4 |
S |
$19.20 |
$15,360 |
D/D |
(800) |
0 |
|
- |
|
97 Records found
|
|
Page 3 of 4 |
|
|
0.42 (4.55%) 
